Tumor Response

Studied in DESTINY-Gastric01,

Tumor response and disease control rates for ENHERTU and irinotecan or paclitaxel

ENHERTU: Best Percent Change From Baseline in the Sum of Longest Diameters of Measurable Tumors (Exploratory Endpoint)2,a

ENHERTU tumor response – an exploratory endpoint ENHERTU tumor response – an exploratory endpoint
  • 84.1% disease control rate (DCR) with ENHERTU (n=106/126)5,c

Irinotecan or Paclitaxel: Best Percent Change From Baseline in the Sum of Longest Diameters of Measurable Tumors (Exploratory Endpoint)2,a

Chemotherapy (irinotecan or paclitaxel) tumor response – an exploratory endpoint Chemotherapy (irinotecan or paclitaxel) tumor response – an exploratory endpoint
  • 61.3% DCR with irinotecan or paclitaxel (n=38/62)5,c

CR, complete response; DCR, disease control rate; ICR, independent central review; PR, partial response; SD, stable disease.

aThe analyses included patients who had both baseline and postbaseline target-lesion assessments according to ICR.

bSix patients (2 in the ENHERTU arm and 4 in the irinotecan or paclitaxel arm) were excluded from this analysis because they did not undergo postbaseline tumor assessment.2

cDCR=CR+PR+SD.5

  • DESTINY-Gastric01 studied 188 adult patients with HER2+ aGC who had received ≥2 prior lines of treatment, including a trastuzumab-based regimen
Ready to learn more about ENHERTU?